首页 > 市场调查报告书 > 製药

癌症

市场调查报告书

商品编码

1750227

癌症的γδT细胞疗法的全球市场:市场趋势，技术平台，临床试验预测(2031年)

Global Gamma Delta T Cell Cancer Therapy Market Trends, Technology Platforms & Clinical Trials Outlook 2031

出版日期: 2025年06月01日 | 出版商:

KuicK Research | 英文 210 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球癌症的γδT细胞疗市场趋势，技术平台，临床试验预测(2031年)报告的结论

临床试验中的γδT细胞抗癌疗法：>25+种疗法
最高研发阶段：II/III期
截至2025年6月，尚无γδT细胞疗法实现商业化
美国和中国γδT细胞疗法临床试验占主导地位：20+种疗法
γδT细胞疗法临床试验洞察：依公司、国家、适应症、阶段划分
γδT细胞疗法技术平台公司洞察：15+个平台
以适应症划分的γδT细胞疗法市场潜力

适应性γδT细胞 (Yδ)免疫疗法是一种新型免疫疗法，利用独特的T细胞亚群来辨识并摧毁癌细胞。典型的αβ（aB）T细胞辨识由主要组织相容性复合体（MHC）分子呈现的抗原，而YδT细胞则以MHC非依赖的方式被压力诱导的配体和磷酸化抗原活化。这使得它们能够检测并针对多种肿瘤，包括那些传统免疫警戒机制未针对的肿瘤。 YδT细胞兼具先天免疫和适应性免疫的特性，并具有即时应答和免疫记忆的能力，使其成为现成的过继细胞疗法的理想候选者。

在癌症治疗中，YδT细胞因其无需技术难度高且成本高昂的肿瘤特异性抗原或基因改造即可摧毁恶性细胞的潜力而备受关注。其固有的细胞毒性，加上可以使用同种异体细胞（来自健康捐赠者）的可能性，为大规模生产和廉价治疗提供了途径。迄今为止，大多数临床研发都集中在血液系统恶性肿瘤领域，该领域前景广阔。 Yδ T 细胞可以侵入骨髓和其他淋巴器官，并透过释放细胞激素、直接细胞毒性和改变肿瘤微环境来影响肿瘤。

迫切需要新的癌症疗法，尤其是像急性骨髓性白血病 (AML) 这样的血液系统癌症，这类癌症容易復发或对常规疗法产生抗药性。对于缓解后復发或有残留疾病 (MRD) 的患者，治疗选择有限，预后通常较差。 Yδ T 细胞疗法具有独特的优势，可以填补这一空白，它提供了一种可能有效、安全且易于获取的现成产品，并且不存在自体 T 细胞疗法的后勤问题，例如生产暂停和患者个体差异。

TC Biopharm 在该领域的临床开发中处于领先地位。该公司最先进的候选产品 OmnImmune（原名 TCB-002）目前正在进行针对急性髓性白血病 (AML) 的关键性 II/III 期临床试验。 OmnImmune 是一种同种异体 Yδ T 细胞疗法，旨在快速靶向并摧毁癌细胞，同时避免对正常组织的损害。该临床计画是全球 Yδ T 细胞产品线中最先进的计画之一，彰显了 TC Biopharm 在该领域新兴的领导地位。除了 OmnImmune，该公司还有多个 Yδ T 细胞候选药物正在开发中，用于治疗各种癌症。

TC Biopharm 近期最重要的进展之一是其 TCB008 候选药物的开发，该药物目前正在进行 II 期 ACHIEVE 试验。 2025 年 6 月，该公司报告称，B 组首例患者（先前復发且可检测到微小残留疾病 (MRD)）在接受两次给药后实现了完全分子缓解 (CRT)。治疗后检测不到NPM1转录本显示疗效显着且持久，展现了TCB008作为血液系统癌症缓解后治疗的潜力。这项结果凸显了YδT细胞强大的标靶免疫功能，并证明了其作为一种新型治疗策略的作用。

在全球范围内，大多数对YδT细胞的研究仍停留在血液系统恶性肿瘤领域，针对实体肿瘤的项目较少。部分原因是实体瘤利用更复杂的微环境和免疫逃脱机制。然而，人们正在尝试将YδT细胞疗法应用于这些更具课题性的治疗环境。从地区来看，美国公司在YδT细胞疗法市场占据主导地位，其次是越来越多的中国公司。这些地区在细胞疗法设施和技术方面投入了大量资金，促进了该疗法从实验室到临床的快速转变。

展望未来，YδT细胞疗法前景光明，但其在实体肿瘤中的临床验证仍需持续。生产和生物标记驱动策略的进步有望将YδT细胞的应用扩展到更多癌症类型。在TC Biopharm等领导企业的引领下，该领域可望为肿瘤学领域尚未满足的重大需求提供改变生命的治疗方案。

Gamma Delta T Cell Therapies In Clinical Trials: > 25 Therapies
Highest Phase Of Development: Phase II/III
As Of June'2025 No Gamma Delta T Cells Therapy Is Commercially Available
US & China Dominating Gamma Delta T Cell Therapies Clinical Trials Landscape: > 20 Therapies
Gamma Delta T Cell Therapy Clinical Trials Insight By Company, Country, Indication and Phase
Gamma Delta T Cell Therapies Technology Platforms Insight By Company : > 15 Platforms
Gamma Delta T Cell Therapy Market Potential By Indications Based On Adoption Rates

Adoptive gamma delta (Yδ) T cell therapy is a novel type of immunotherapy that utilizes a unique subset of T cells to recognize and destroy cancer cells. While typical alpha-beta (aB) T cells identify antigens presented by major histocompatibility complex (MHC) molecules, Yδ T cells are activated by stress induced ligands and phosphoantigens in an MHC independent fashion. This enables them to detect and target a wide variety of tumor types, including those that are not targeted by conventional immune vigilance. Yδ T cells possess characteristics of both innate and adaptive immunity, allowing them to have the ability for immediate response and immune memory, which make them particularly good candidates for off-the-shelf adoptive cell therapies.

In cancer, Yδ T cells are under investigation for their potential to destroy malignant cells without the requirement of tumor-specific antigens or genetic modifications, which are technically demanding and expensive. Their intrinsic cytotoxicity, along with the possibility of allogeneic utilization (from healthy donors), provides access to the availability of mass producible, inexpensive therapies. The majority of clinical research and development to date has been in hematological malignancies, where they have been especially promising. Yδ T cells are able to penetrate the bone marrow and other lymphoid organs and exert tumor effects there through cytokine release, direct cytotoxicity, and changing the microenvironment of the tumor.

The demand for novel cancer therapies is pressing, especially in blood cancers like acute myeloid leukemia (AML), which tend to relapse or are resistant to conventional therapies. Options for patients who relapse following remission or who have residual disease (MRD) are limited, and prognosis is usually poor. Yδ T cell therapies are in a unique position to bridge this gap, providing a potentially effective, safe, and off-the-shelf product that can be delivered without the logistical issues of autologous T cell therapies, including manufacturing hold-ups or patient variability.

TC Biopharm is leading the way in clinical development in this area. The company's most advanced product candidate, OmnImmune (formerly TCB-002), is in a pivotal Phase 2/3 trial for AML. OmnImmune is an allogeneic Yδ T cell therapy engineered to quickly target and destroy cancer cells while avoiding damage to normal tissue. This clinical program is one of the most advanced in the global Yδ T cell pipeline, highlighting TC Biopharm's growing leadership within the domain. Besides OmnImmune, the company has a number of other Yδ T cell candidates in development for various cancer indications.

One of the most significant recent advances from TC Biopharm is the development of its candidate TCB008, which is under investigation in the Phase 2 ACHIEVE trial. The firm reported in June 2025 that the first patient in Cohort B, who had relapsed previously with detectable MRD, reached complete molecular remission following two doses. A lack of detectable NPM1 transcripts after treatment signifies a profound and lasting response, which identifies TCB008 as a promising post-remission therapy for blood cancers. This achievement demarcates the potent, targeted immune function of Yδ T cells and substantiates their role as a new therapeutic strategy.

Globally, most of the research studies on Yδ T cells remains on hematologic malignancies, and there are fewer programs directed at solid tumors. This is partly a result of the more sophisticated microenvironments and the immune evasion mechanisms utilized by solid cancers. However, attempts are being made to apply Yδ T cell treatments to these more difficult contexts. Geographically, US-based players dominate the Yδ T cell therapy market, followed by increasing numbers of Chinese firms. These regions have made heavy investment in cell therapy facilities and technology, facilitating quicker translation from bench to bedside.

Moving forward, the prospects for Yδ T cell therapy are bright but will necessitate continued clinical validation, most importantly in solid tumors. With advances in manufacturing technologies and biomarker-driven strategies, the use of Yδ T cells may extend to more types of cancers. With leaders such as TC Biopharm at the forefront, the field is on track to provide life changing treatments for critical unmet needs in cancer domain.

1. Introduction To Gamma Delta T Cell Therapy

1.1 Emerging Role of T Cell Based Immunotherapies
1.2 Overview of Gamma Delta T Cell Therapy
1.3 Gamma Delta T Cell Therapy v/s Conventional Therapies

2. Role of Gamma Delta T Cells in Cancer

2.1 Gamma Delta T Cells in Cancer Progression
2.2 Anti Tumor Activity of Gamma Delta T Cells
2.3 Adopted Approaches for Gamma Delta T Cell Therapy

3. Advanced Combination Strategies In Gamma Delta T Cell Therapy

4. Gamma Delta T Cell Therapy Market Overview

4.1 Current Market Scenario
4.2 Future R&D & Commercial Opportunities
4.3 Market Potential of Gamma Delta T Cell Therapy Market
4.4 Technology Platforms For Gamma Delta T Cell Therapy
4.5 Favorable Market Growth Parameters
4.6 Key Challenges To Overcome For Future Growth

5. Global Gamma Delta T Cell Therapy Clinical Trials Overview

5.1 By Phase
5.2 By Country
5.3 By Company
5.4 By Indication
5.5 By Priority Status

6. Global Gamma Delta T Cell Therapy Clinical Trials Insight By Company, Country, Indication & Phase

6.1 Research
6.2 Preclinical
6.3 Phase I
6.4 Phase I/II
6.5 Phase II
6.6 Phase II/III

7. Gamma Delta T Cell Therapy In Leukemia

7.1 Ongoing Clinical Research & Development Trends
7.2 Future Market Opportunity of Gamma Delta T Cells In Leukemia

8. Gamma Delta T Cell Therapy In Lung Cancer

8.1 Ongoing Clinical Research & Development Trends
8.2 Future Market Opportunity of Gamma Delta T Cell Therapy In Lung Cancer

9. Gamma Delta T Cells In Breast Cancer

9.1 Ongoing Clinical Research & Development Trends
9.2 Future Market Opportunity of Gamma Delta T Cell Therapy In Breast Cancer

10. Gamma Delta T Cells in Colorectal Cancer

10.1 Ongoing Clinical Research & Development Trends
10.2 Future Market Potential of Gamma Delta T Cell Therapy in Colorectal Cancer

11. Gamma Delta T Cells In Pancreatic Cancer

11.1 Ongoing Clinical Research & Development Trends
11.2 Future Market Potential of Gamma Delta Therapy In Pancreatic Cancer

12. Gamma Delta T Cells In Lymphoma

12.1 Ongoing Clinical Research & Development Trends
12.2 Future Market Potential of Gamma Delta Therapy In Lymphoma

13. Gamma Delta T Cell Therapy In Brain Tumors

13.1 Research & Development In Brain Tumors
13.2 Future Market Potential of Gamma Delta Therapy In Brain Tumors

14. Gamma Delta T Cell Therapy In Head & Neck Cancer

14.1 Research & Development In Head & Neck Cancer
14.2 Future Market Potential of Gamma Delta Therapy In Head & Neck Cancer

15. Competitive Landscape

15.1 Acepodia
15.2 Adicet
15.3 Appia Bio
15.4 Cytomed Therapeutics
15.5 Century Therapeutics
15.6 Expression Therapeutics
15.7 Immatics
15.8 IN8bio
15.9 JY BioMed
15.10 Legend Biotech
15.11 Luminary Therapeutics
15.12 PhosphoGam
15.13 Takeda
15.14 TC Biopharm
15.15 ViGenCell

简介目录图表

List of Figures

Figure 1-1: History Of T Cell Based Immunotherapy
Figure 1-2: Gamma Delta T cell Therapy
Figure 1-3: Stimulants of Gamma Delta T Cells
Figure 1-4: CAR T Cell Therapy Limitations
Figure 1-5: Limitations of TIL
Figure 1-6: Limitations of Monoclonal Antibodies
Figure 1-7: Drawbacks of Chemotherapeutic Drugs
Figure 2-1: Pro-Tumor Role of Gamma Delta T Cells
Figure 2-2: Antigen Presentation Functions Of Gamma Delta T Cells
Figure 2-3: Anti-Tumor Activity of Gamma Delta T-Cells
Figure 2-4: Gamma Delta T Cell Bispecific Antibodies - Mechanism of Action
Figure 2-5: Functional Advantages Of Yo T Cells for CAR T Cancer Therapy
Figure 2-6: CAR Yo T Cells - Mechanism of Action
Figure 4-1: Gamma Delta T Cell Therapy Market - Future Opportunities
Figure 4-2: Global - Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-3: Global - Gamma Delta T Cell Therapy Market Opportunity By 1% Of Total Cell Therapy Market (US$ Billion), 2025 -2031
Figure 4-4: Global - Gamma Delta T Cell Therapy Market Opportunity By 2% Of Total Cell Therapy Market (US$ Billion), 2025 -2031
Figure 4-5: Global - Gamma Delta T Cell Therapy Market Opportunity By 3% Of Total Cell Therapy Market (US$ Billion), 2025 -2031
Figure 4-6: Global - Gamma Delta T Cell Therapy Market Opportunity By 4% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-7: Global - Gamma Delta T Cell Therapy Market Opportunity By 5% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-8: Global - Gamma Delta T Cell Therapy Market Opportunity By 6% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-9: Global - Gamma Delta T Cell Therapy Market Opportunity By 7% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-10: Global - Gamma Delta T Cell Therapy Market Opportunity By 8% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-11: Global - Gamma Delta T Cell Therapy Market Opportunity By 9% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-12: Global - Gamma Delta T Cell Therapy Market Opportunity By 10% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-13: IN8bio - DeltEx DRI Auto
Figure 4-14: Diamond AI - Prediction Engine
Figure 4-15: Diamond AI - Immune Surveillance
Figure 4-16: Acepodia - Antibody-Cell Conjugation
Figure 4-17: Lava Therapeutics - Gammabody Platform
Figure 4-18: Adicet Bio - Gamma Delta Cell Platform
Figure 4-19: ADI-001 - Gamma Delta Cell Therapy
Figure 4-20: Century Therapeutics - Allo-Evasion
Figure 4-21: ViGenCell - ViRanger Platform
Figure 4-22: Legend Biotech - CAR-Yo T Platform
Figure 4-23: Immatics - ACTallo(R) Manufacturing Process
Figure 4-24: Gamma Delta T Cell Platform - carxall
Figure 4-25: Proprietary Manufacturing & Cell Platform Process - Adicet Bio
Figure 4-26: CAR-Yo T Cell - CytoMed Therapeutics
Figure 4-27: iPSC-Yo NKT Cells - CytoMed Therapeutics
Figure 4-28: Luminary Therapeutics - TcBuster Benefits
Figure 4-29: SSC Cell Platform - Core Foundations
Figure 4-30: Acua Platform - Appia Bio
Figure 4-31: Gamma Delta T Cell Therapy Market Drivers & Opportunities
Figure 4-32: Gamma Delta T Cell Therapy Market Challenges & Restraints
Figure 5-1: Global - Gamma Delta T Cell Therapy Clinical Trials By Phase (Numbers), 2025 Till 2031
Figure 5-2: Global - Gamma Delta T Cell Therapy Clinical Trials By Country (Numbers), 2025 Till 2031
Figure 5-3: Global - Gamma Delta T Cell Therapy Clinical Trials By Company (Numbers), 2025 Till 2031
Figure 5-4: Global - Gamma Delta T Cell Therapy Clinical Trials By Indication (Numbers), 2025 Till 2031
Figure 5-5: Global - Gamma Delta T Cell Therapy Clinical Trials By Priority Status (Numbers), 2025 Till 2031
Figure 7-1: Benefits of Gamma Delta T Cells in Leukemia
Figure 7-2: CD33CART Phase 1/2 (NCT03971799) Study - Initiation & Completion Year
Figure 7-3: ACHIEVE (TCB008-001) Phase 2 (NCT05358808) Study - Initiation & Completion Year
Figure 7-4: ACHIEVE2 (TCB008-003) Phase 1 (NCT06463327) Study - Initiation & Completion Year
Figure 7-5: INB-100 Phase 1 (NCT03533816) Study - Initiation & Completion Year
Figure 7-6: Mechanism of Action of VY9/CD123 Bispecific Antibody
Figure 7-7: Global - Estimated Leukemia Cases, 2025-2031
Figure 7-8: US - Estimated Leukemia Cases, 2025-2031
Figure 7-9: Europe - Estimated Leukemia Cases, 2025-2031
Figure 7-10: China - Estimated Leukemia Cases, 2025-2031
Figure 7-11: Japan - Estimated Leukemia Cases, 2025-2031
Figure 8-1: Role of Gamma Delta T Cells in Lung Cancer
Figure 8-2: DELTACEL-01 Phase 1 (NCT06069570) Study - Initiation & Completion Year
Figure 8-3: Global - Estimated Lung Cancer Cases, 2025-2031
Figure 8-4: US - Estimated Lung Cancer Cases, 2025-2031
Figure 8-5: Europe - Estimated Lung Cancer Cases, 2025-2031
Figure 8-6: China - Estimated Lung Cancer Cases, 2025-2031
Figure 8-7: Japan - Estimated Lung Cancer Cases, 2025-2031
Figure 9-1: Global - Estimated Breast Cancer Cases, 2025-2031
Figure 9-2: US - Estimated Breast Cancer Cases, 2025-2031
Figure 9-3: Europe - Estimated Breast Cancer Cases, 2025-2031
Figure 9-4: China - Estimated Breast Cancer Cases, 2025-2031
Figure 9-5: Japan - Estimated Breast Cancer Cases, 2025-2031
Figure 10-1: Role of Gamma Delta T Cells in Colorectal Cancer
Figure 10-2: Mechanism Underlying B7-H3 Regulating Yo T Cells Killing Colon Cancer Cells
Figure 10-3: SGNEGFRd2-001 Phase I (NCT05983133) Study - Initiation & Completion Year
Figure 10-4: Global - Estimated Colorectal Cancer Cases, 2025-2031
Figure 10-5: US - Estimated Colorectal Cancer Cases, 2025-2031
Figure 10-6: Europe - Estimated Colorectal Cancer Cases, 2025-2031
Figure 10-7: China - Estimated Colorectal Cancer Cases, 2025-2031
Figure 10-8: Japan - Estimated Colorectal Cancer Cases, 2025-2031
Figure 11-1: Auspicious Outcomes Gamma Delta T Cell Therapy
Figure 11-2: Role of Gamma Delta T Cells in Pancreatic Cancer Progression
Figure 11-3: Global - Estimated Pancreatic Cancer Cases, 2025-2031
Figure 11-4: US - Estimated Pancreatic Cancer Cases, 2025-2031
Figure 11-5: Europe - Estimated Pancreatic Cancer Cases, 2025-2031
Figure 11-6: China - Estimated Pancreatic Cancer Cases, 2025-2031
Figure 11-7: Japan - Estimated Pancreatic Cancer Cases, 2025-2031
Figure 12-1: ACE1831 Phase I (NCT05653271) Study - Initiation & Completion Year
Figure 12-2: ADI-001 Phase I (NCT04735471) Study - Initiation & Completion Year
Figure 12-3: Global - Estimated Lymphoma Cases, 2025-2031
Figure 12-4: US - Estimated Lymphoma Cases, 2025-2031
Figure 12-5: Europe - Estimated Lymphoma Cases, 2025-2031
Figure 12-6: China - Estimated Lymphoma Cases, 2025-2031
Figure 12-7: Japan - Estimated Lymphoma Cases, 2025-2031
Figure 13-1: INB-400 Phase 1/2 (NCT05664243) Study - Initiation & Completion Year
Figure 13-2: IN8bio - Autologous (INB-400) & Allogeneic (INB-410) Candidates
Figure 13-3: UAB 1773 Phase 1 (NCT04165941) Study - Initiation & Completion Year
Figure 13-4: Global - Estimated Brain Cancer Cases, 2025-2031
Figure 13-5: US - Estimated Brain Tumor Cases, 2025-2031
Figure 13-6: Europe - Estimated Brain Tumor Cases, 2025-2031
Figure 13-7: China - Estimated Brain Tumor Cases, 2025-2031
Figure 13-8: Japan - Estimated Brain Tumor Cases, 2025-2031
Figure 14-1: Acepodia Biotech Clinical Pipeline Insight
Figure 14-2: Pfizer & Lava Therapeutics Collaboration
Figure 14-3: SGN-EGFRd2 Phase 1 (NCT05983133) Study - Initiation & Completion Year
Figure 14-4: Global - Estimated Head & Neck Cancer Cases, 2025-2031
Figure 14-5: US - Estimated Head & Neck Cancer Cases, 2025-2031
Figure 14-6: Europe - Estimated Head & Neck Cancer Cases, 2025-2031
Figure 14-7: China - Estimated Head & Neck Cancer Cases, 2025-2031
Figure 14-8: Japan - Estimated Head & Neck Cancer Cases, 2025-2031

List of Tables

Table 3-1: Ongoing Clinical Trials For Combination Of Gamma Delta T Cell Therapy
Table 7-1: Global - Estimated Adoption Rate Of Gamma Delta T Cell In Leukemia, 2025-2031
Table 7-2: US - Estimated Adoption Rate Of Gamma Delta T Cell In Leukemia, 2025-2031
Table 7-3: Europe - Estimated Adoption Rate Of Gamma Delta T Cell In Leukemia, 2025-2031
Table 7-4: China - Estimated Adoption Rate Of Gamma Delta T Cell In Leukemia, 2025-2031
Table 7-5: Japan - Estimated Adoption Rate Of Gamma Delta T Cell In Leukemia, 2025-2031
Table 8-1: Global - Estimated Adoption Rate Of Gamma Delta T Cell In Lung Cancer, 2025-2031
Table 8-2: US - Estimated Adoption Rate Of Gamma Delta T Cell In Lung Cancer, 2025-2031
Table 8-3: Europe - Estimated Adoption Rate Of Gamma Delta T Cell In Lung Cancer, 2025-2031
Table 8-4: China - Estimated Adoption Rate Of Gamma Delta T Cell In Lung Cancer, 2025-2031
Table 8-5: Japan - Estimated Adoption Rate Of Gamma Delta T Cell In Lung Cancer, 2025-2031
Table 9-1: Global - Estimated Adoption Rate Of Gamma Delta T Cell In Breast Cancer, 2025-2031
Table 9-2: US - Estimated Adoption Rate Of Gamma Delta T Cell In Breast Cancer, 2025-2031
Table 9-3: Europe - Estimated Adoption Rate Of Gamma Delta T Cell In Breast Cancer, 2025-2031
Table 9-4: China - Estimated Adoption Rate Of Gamma Delta T Cell In Breast Cancer, 2025-2031
Table 9-5: Japan - Estimated Adoption Rate Of Gamma Delta T Cell In Breast Cancer, 2025-2031
Table 10-1: Global - Estimated Adoption Rate Of Gamma Delta T Cell In Colorectal Cancer, 2025-2031
Table 10-2: US - Estimated Adoption Rate Of Gamma Delta T Cell In Colorectal Cancer, 2025-2031
Table 10-3: Europe - Estimated Adoption Rate Of Gamma Delta T Cell In Colorectal Cancer, 2025-2031
Table 10-4: China - Estimated Adoption Rate Of Gamma Delta T Cell In Colorectal Cancer, 2025-2031
Table 10-5: Japan - Estimated Adoption Rate Of Gamma Delta T Cell In Colorectal Cancer, 2025-2031
Table 11-1: Global - Estimated Adoption Rate Of Gamma Delta T Cell In Pancreatic Cancer, 2025-2031
Table 11-2: US - Estimated Adoption Rate Of Gamma Delta T Cell In Pancreatic Cancer, 2025-2031
Table 11-3: Europe - Estimated Adoption Rate Of Gamma Delta T Cell In Pancreatic Cancer, 2025-2031
Table 11-4: China - Estimated Adoption Rate Of Gamma Delta T Cell In Pancreatic Cancer, 2025-2031
Table 11-5: Japan - Estimated Adoption Rate Of Gamma Delta T Cell In Pancreatic Cancer, 2025-2031
Table 12-1: Global - Estimated Adoption Rate Of Gamma Delta T Cell In Lymphoma, 2025-2031
Table 12-2: US - Estimated Adoption Rate Of Gamma Delta T Cell In Lymphoma, 2025-2031
Table 12-3: Europe - Estimated Adoption Rate Of Gamma Delta T Cell In Lymphoma, 2025-2031
Table 12-4: China - Estimated Adoption Rate Of Gamma Delta T Cell In Lymphoma, 2025-2031
Table 12-5: Japan - Estimated Adoption Rate Of Gamma Delta T Cell In Lymphoma, 2025-2031
Table 13-1: Global - Estimated Adoption Rate Of Gamma Delta T Cell In Brain Tumors, 2025-2031
Table 13-2: US - Estimated Adoption Rate Of Gamma Delta T Cell In Brain Tumors, 2025-2031
Table 13-3: Europe - Estimated Adoption Rate Of Gamma Delta T Cell In Brain Tumors, 2025-2031
Table 13-4: China - Estimated Adoption Rate Of Gamma Delta T Cell In Brain Tumors, 2025-2031
Table 13-5: Japan - Estimated Adoption Rate Of Gamma Delta T Cell In Brain Tumors, 2025-2031
Table 14-1: Global - Estimated Adoption Rate Of Gamma Delta T Cell In Head & Neck Cancers, 2025-2031
Table 14-2: US - Estimated Adoption Rate Of Gamma Delta T Cell In Head & Neck Cancers, 2025-2031
Table 14-3: Europe - Estimated Adoption Rate Of Gamma Delta T Cell In Head & Neck Cancer, 2025-2031
Table 14-4: China - Estimated Adoption Rate Of Gamma Delta T Cell In Head & Neck Cancers, 2025-2031
Table 14-5: Japan - Estimated Adoption Rate Of Gamma Delta T Cell In Head & Neck Cancer, 2025-2031

02-2729-4219

+886-2-2729-4219

License/价格

癌症的γδT细胞疗法的全球市场:市场趋势，技术平台，临床试验预测(2031年)

Global Gamma Delta T Cell Cancer Therapy Market Trends, Technology Platforms & Clinical Trials Outlook 2031

目录

第1章 γδT细胞疗法的简介

第2章癌症的γδT细胞所扮演的角色

第3章 γδT细胞疗法能放的高度的并用策略

第4章 γδT细胞疗法市场概要

第5章全球γδT细胞疗法的临床试验概要

第6章世界γδT细胞疗法临床试验的洞察，企业，国家，适应症，各相

第7章白血病的γδT细胞疗法

第8章肺癌症的γδT细胞疗法

第9章乳癌的γδT细胞

第10章大肠癌症的γδT细胞

第11章胰臟癌症的γδT细胞

第12章淋巴瘤的γδT细胞

第13章脑瘤的γδT细胞疗法

第14章头颈椎癌症的γδT细胞疗法

第15章竞争情形